News

Under the transaction, Exact retained exclusive worldwide rights to its colorectal cancer screening and stool-based DNA testing intellectual property, and will receive a share of Genzyme’s sublicensing income

As the first company to file an abbreviated new drug application containing a paragraph IV certification for this product, Teva has received a 180-day period of marketing exclusivity.

QuantRx expects that the product will be launched by Church & Dwight under its First Response brand and will be available at the retail level in the second

Highlights Total operating expenses increased $2,225 or less than 1% vs. the prior year’s comparable quarter. Operating loss for the quarter was $61,060 vs. $62,913 for the prior

The lead clinical development program for dirucotide is for secondary progressive multiple sclerosis (MS) where it is being evaluated in two ongoing Phase III trials in the US,

The establishment of a US-based R&D and commercial operation represents attainment of one of the Helsinn Group’s corporate strategic goals. Helsinn has appointed Franco Vecchi, who is already

According to the company, the E coli/P aeruginosa PNA FISH is the first-ever test for identifying E coli and P aeruginosa directly from positive blood cultures and the

The Phase II study is a single-blind, placebo-controlled, dose-escalation trial expected to enroll a total of 130 patients with anemia of chronic kidney disease (CKD) who are not

Kapidex (30mg and 60mg) is the first proton pump inhibitor (PPI) with a dual delayed release formulation designed to provide two separate releases of medication. The approval was